VEA - Vanguard FTSE Developed Markets ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
43.34
+0.15 (+0.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close43.19
Open43.24
Bid0.00 x 39400
Ask0.00 x 1100
Day's Range43.23 - 43.39
52 Week Range41.57 - 47.89
Volume5,705,089
Avg. Volume8,283,371
Net Assets109.53B
NAV43.08
PE Ratio (TTM)N/A
Yield3.05%
YTD Return-2.32%
Beta (3y)0.90
Expense Ratio (net)0.07%
Inception Date2007-07-20
Trade prices are not sourced from all markets
  • ETF Trends28 days ago

    4 International ETFs To Capitalize on Potential Turnaround

    The disconnect between U.S. equities and international stocks is growing wider, but this disparity will not last forever. After the recent underperformance in foreign markets, exchange traded fund investors may find an opportune moment to jump into relatively cheap global equities. For instance, if one looks at price momentum – it is positive for US stocks and negative for Europe and Emerging markets across all relevant lookback windows [one month, three months, six months and 12 months].

  • WisdomTree Launches Two Active Multifactor ETFs
    Zackslast month

    WisdomTree Launches Two Active Multifactor ETFs

    Wisdomtree has launched actively managed multifactor ETFs, EMMF and DWMF.

  • 1H Asset Flow Roundup: What's Hot & What's Not
    Zacks3 months ago

    1H Asset Flow Roundup: What's Hot & What's Not

    Stocks across the globe have suffered their worst first half in a year since 2010, wiping out trillions of dollars from the MSCI's 47-country world index. Inside the hot and flop ETFs in terms of fund flows.

  • PR Newswire3 months ago

    Vanguard to Further Drive Down the Cost of Investing by Broadening Commission-Free ETF Trades

    VALLEY FORGE, Pa., July 2, 2018 /PRNewswire/ -- Vanguard today announced substantial reductions in the cost of investing with the firm by providing commission-free online transactions for the vast majority of ETFs. Vanguard, which has offered commission-free transactions of Vanguard ETFs since 2010, is broadening access beyond the company's 77 low-cost ETFs to nearly 1,800 offerings, including ETFs from BlackRock, Schwab, and SSgA. "Vanguard has led the industry in reducing the cost and complexity of investing for all investors for more than four decades.

  • Business Wire3 months ago

    E*TRADE Adds Several of Today’s Most Popular ETFs to Commission-Free ETF Lineup

    E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr

  • 5 Passive ETFs Soaring in Popularity on Millennials' Choice
    Zacks3 months ago

    5 Passive ETFs Soaring in Popularity on Millennials' Choice

    Millennials are betting big on ETFs: Will the ride continue?

  • Analysts’ Recommendations for GlaxoSmithKline in May
    Market Realist4 months ago

    Analysts’ Recommendations for GlaxoSmithKline in May

    GlaxoSmithKline (GSK) reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates of 24.21 pence on revenue of 7.20 billion pounds, in Q1 2018.

  • Is iShares Edge MSCI Multifactor Intl ETF (INTF) a Hot ETF Right Now?
    Zacks4 months ago

    Is iShares Edge MSCI Multifactor Intl ETF (INTF) a Hot ETF Right Now?

    Smart Beta ETF report for INTF

  • AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
    Market Realist4 months ago

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.

  • GlaxoSmithKline’s Pharmaceutical Business in 1Q18
    Market Realist5 months ago

    GlaxoSmithKline’s Pharmaceutical Business in 1Q18

    GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products. The Pharmaceuticals business segment reported revenues of ~4.0 billion pounds in 1Q18.

  • Benzinga5 months ago

    A Rapidly Growing Developed Markets ETF

    Some new exchange-traded funds are well-timed. Others, not so much. To be fair, good timing with new ETFs is often a matter of coincidence, but as the old saying goes, “it's better to be lucky than good.” ...

  • InvestorPlace5 months ago

    7 Vanguard ETFs for Buy-and-Hold Investors

    Compared to rivals such as iShares and State Street’s SPDR brand, Vanguard’s lineup of exchange-traded funds (ETFs) is small.

  • Benzinga5 months ago

    Demand For International ETFs Remains Strong

    One of the more notable themes in the world of exchange-traded funds last year was investors affinity for international equity funds. When 2017 drew to a close, five of the year's top 10 asset-gathering ...

  • Wining ETF Areas of March
    Zacks6 months ago

    Wining ETF Areas of March

    Inside the ETFs that raked in sizable assets in March.

  • March Madness ETF Prediction and Sweet 16 Picks
    Zacks6 months ago

    March Madness ETF Prediction and Sweet 16 Picks

    The excitement surrounding the tournament and its impact on the stock world has led investors to look at ETFs that could act as a proxy for the game.

  • Investopedia6 months ago

    Short Interest Rises in Popular International, Bond ETFs

    Ahead of this week's Fed meeting, short interest rose in some rate-sensitive ETFs.

  • Weekly ETF Roundup: International & Bond Win, US Equity Lags
    Zacks7 months ago

    Weekly ETF Roundup: International & Bond Win, US Equity Lags

    Inside the ETFs that gained investor's attraction last week.

  • Novartis’s 4Q17 Earnings: Alcon Business
    Market Realist7 months ago

    Novartis’s 4Q17 Earnings: Alcon Business

    Must-Read Notes on Novartis’s 4Q17 and 2017 Earnings

  • Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline
    Market Realist7 months ago

    Multiple Myeloma May Be Strong Growth Area for GlaxoSmithKline

    GlaxoSmithKline (GSK) estimates that almost 65% of the global multiple myeloma (or MM) drug sales are realized in the US. The demand in the MM segment is mainly driven by the aging population, which has resulted in rising annual incidence by around 2% for the disease. Currently, Johnson & Johnson’s (JNJ) anti-CD38 monoclonal antibody, Darzalex (daratumumb) is witnessing rapid uptake in the MM segment due to its higher efficacy as compared to the previous standard of care therapy.

  • AstraZeneca’s 4Q17 Earnings: Analyst Estimates
    Market Realist8 months ago

    AstraZeneca’s 4Q17 Earnings: Analyst Estimates

    AstraZeneca’s 4Q17 Earnings on February 2: What to ExpectA look at AstraZeneca

  • 2-Drug HIV Regimens Expected to Boost GlaxoSmithKline’s Revenues
    Market Realist8 months ago

    2-Drug HIV Regimens Expected to Boost GlaxoSmithKline’s Revenues

    On November 21, 2017, the U.S. Food and Drug Administration (or FDA) approved Jucala, a two-drug oral regimen comprising of dolutegravir and rilpivirine for patients suffering with HIV-1 infections who have not demonstrated treatment failure or history of drug resistance to the individual components of the new therapy. Juluca is commercialized by ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer (PFE), and Shinogi. Since the current standard of care includes three or more drugs, the two drug regimen could help reduce toxicity levels for treated patients.

  • GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017
    Market Realist8 months ago

    GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017

    GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments. The company has estimated global asthma prevalence to be around 250 million with 40% of the treated patients continuing to witness symptoms that affect the quality of their lives. To capitalize on this unmet demand, GlaxoSmithKline aims to deliver the right inhaled corticosteroid (or ICS) or combination regimen to the right patients and to ensure proper drug adherence.